Life (Science) Lessons: The Hows And Whos To Play Biotech


After particularly rough endings to 2015 and 2016, iShares NASDAQ Biotechnology Index has had "a rockstar of a year," and the last two weeks, in particular, have seen significant inflows - about $400 million - into industry ETFs. "I think with respect to the pharma and the biotech industry, the current status quo is a good place for being a drug executive, because you have continuing drivers of demographics, you have continuing solid pricing, you don't have the fears of the industry pricing getting slashed, so I think people in our industry are breathing a sigh of relief," Paul Yook, co-founder of LifeSci Index Partners , said on the Sept.



from Biotech News